Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  irinotecan hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 536 for your search:
Start Over
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Completed
Age: 18 to 85
Sponsor: Other
Protocol IDs: COLOGEN, NCT00138060
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000574159, CHUL-BIO-COLON, INCA-RECF0356, RECF0356, NCT00559676
Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 21
Sponsor: Other
Protocol IDs: PK01/16/08, NCT00808184
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CPT_08_001, NCT01271582
FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
Phase: Phase IV
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: DERMATUX, NCT01315990
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25753, NCT01588990
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000430100, FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 02-0484-C, NCT00160875
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 01023010 / TOP-003, NCT00284258
Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Other
Protocol IDs: JACCRO GC-05, NCT00639327
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000636983, FFCD-PRODIGE-9, FFCD-0802, EU-20912, EU-21030, EUDRACT-2008-007928-25, EUDRACT-2009-017996-11, FFCD-PRODIGE 9/ FFCD 0802, NCT00952029
Phase III Randomized Study of Irinotecan vs Irinotecan/Fluorouracil/Leucovorin vs Fluorouracil/Leucovorin for Untreated Metastatic Colorectal Cancer (Summary Last Modified 12/98)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-95051, P-UPJOHN-MSKCC-95051, NCI-V96-0913
Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000066151, FRE-GERCOR-C97-3/CPTF308, FRE-C97-3/CPTF301, FRE-C97-3/CPTF308, RP-FRE-C97-3/CPTF308, EU-97044, NCT00003260
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01844, SWOG-C89803, NCCTG-C89803, CDR0000066992, CAN-NCIC-CO15, E-89803, CALGB 89803, C89803, U10CA031946, CLB-89803, CO15, NCT00003835
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-40986, NCT00004885
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01847, N9841, SWOG-N9841, NCCTG-N9841, CDR0000067623, ECOG-N9841, U10CA025224, NCT00005036
Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000067967, FRE-FNCLCC-ACCORD-2, FFCD-9802, EU-20014, NCT00005979
Combination Chemotherapy in Treating Patients With Colorectal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000068113, CLB-9864, E-C9864, C9864, NCT00006103
Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068871, ACRIN-6655, NCT00023868
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP 4174B-307, CDR0000069014, PFIZER-A5961053, RP-64174-V-307, EORTC-40993, PETACC-3, PFIZER-XRP-4174B-307, NCT00026273
Start Over